US OptionsDetailed Quotes
ITOS241220P8000
- 0.27
- +0.16+145.45%
15min DelayClose Dec 12 16:00 ET
0.27High0.27Low
0.27Open0.11Pre Close1 Volume15 Open Interest8.00Strike Price27.00Turnover457.88%IV2.71%PremiumDec 20, 2024Expiry Date0.06Intrinsic Value100Multiplier7DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type-0.3748Delta0.0727Gamma3.83Leverage Ratio-0.1364Theta-0.0010Rho-1.43Eff Leverage0.0043Vega
ITeos Therapeutics Stock Discussion
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet